Recruiting

Epigenetic Regulation

Sponsor:

National Jewish Health

Code:

NCT03145922

Conditions

Sarcoidosis

Sarcoidosis, Pulmonary

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Observational Study

Study Details

Brief summary:

Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, environmental and infectious agents have been associated with sarcoidosis in susceptible hosts. Exposure to these triggers result in inflammation, characterized by activation of CD4+ T-cells, cytokine production, subsequent recruitment of other immune cells, and granuloma formation. Although several genetic markers have been associated with sarcoidosis, none fully explain individual susceptibility or clinical course variability, strongly implicating the environment and epigenetics. We have the ability to generate a map of the epigenetic histone modifications in immune cells via Chromatin Immuno-Precipitation coupled with next generation sequencing (ChIP-seq) and a map of transcriptome profiles via RNA-seq. The availability of histone and transcriptional signatures defining T cell activity in sarcoidosis will help identify the specific molecular programs affected by disease processes and can become the basis for future discovery of novel biomarker diagnostics in a clinical setting.

Conditions

Sarcoidosis

Sarcoidosis, Pulmonary

Study ID

NCT03145922

Start date

Jan, 2016

Status verified date

May, 2020

Completion date

Jan, 2026

Anticipated

Primary completion date

Jan, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Between the ages of 18 and 85
  • Diagnosis of sarcoidosis confirmed by either biopsy or by manifestations consistent with acute sarcoidosis in absence of other known diagnosis.
  • Have a suspected diagnosis of sarcoidosis and is scheduled to undergo a biopsy procedure to confirm a diagnosis of sarcoidosis.
  • Able to tolerate and willing to undergo study procedures

Exclusion Criteria:

  • Current cigarette smoking or smoking within six months prior to the study
  • Currently or recently (<6months) on immunosuppressive therapy
  • Pregnancy
  • Patient inability to participate in the study, such as undergo venipuncture and or BAL

Study Design

Enrollment

45 participants

Anticipated

Interventions and Outcome Measures

Arms

Sarcoidosis

Healthy Controls

Interventions

Observational Study

Observational study utilizing bronchoscopy, and imaging

Primary outcome measure

  • Epigenomic Signature of Sarcoidosis [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Locations

University of California, San Francisco (Parnassus)

Recruiting

San Francisco, California, United States, 94143

Contacts

More Information

Sponsor

National Jewish Health

Last update posted

May 6, 2020

Last verified

May, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Jewish Health on 2020-05-06.